TY - JOUR
T1 - Subcutaneous allergen immunotherapy in the treatment of allergic respiratory disease
AU - Creticos, Peter Socrates
N1 - Funding Information:
From the Division of Allergy and Clinical Immunology, Johns Hopkins School of Medicine, Baltimore, Maryland and Creticos Research Group, Crownsville, Maryland Funding support provided by ALK through an unrestricted educational grant to the American Association of Certified Allergists (AACA). The AACA had full responsibility for the selection of topics and authors, as well as publisher oversight. This manuscript is part of the Allergy & Asthma Proceedings collection of published works referred to as the “Allergen Immunotherapy (AIT) Primer.” The contents of this work reflects the opinion(s) of the author(s) and is not intended to replace published guidelines or the clinician’s medical advice in the doctor-patient relationship PS Creticos is a consultant or has received grants from ASIT, Regeneron, Cliantha-Inflamax/HAL, ALK, Stallergenes Greer, and Greer Labs Supplemental data available at www.IngentaConnect.com Address correspondence to Peter Socrates Creticos, M.D., c/o Creticos Research Group, 1300 Saint Paul’s Way, Crownsville, MD 21032 E-mail address: [email protected] Copyright © 2022, OceanSide Publications, Inc., U.S.A.
Publisher Copyright:
Copyright © 2022, OceanSide Publications, Inc., U.S.A.
PY - 2022/7/1
Y1 - 2022/7/1
N2 - Subcutaneous immunotherapy is recognized as a cornerstone in the management of allergic respiratory disease in patients who are properly characterized with allergy and with allergic rhinoconjunctivis and/or well-controlled asthma, and who are willing to adhere to the rigorous treatment program. A key tenet is that it affords the opportunity to effect long-term clinical remission through its disease-modifying properties. Furthermore, it has the potential to prevent the progression of allergic rhinitis to asthma, prevent new allergen sensitivities, and improve a patient's quality of life.
AB - Subcutaneous immunotherapy is recognized as a cornerstone in the management of allergic respiratory disease in patients who are properly characterized with allergy and with allergic rhinoconjunctivis and/or well-controlled asthma, and who are willing to adhere to the rigorous treatment program. A key tenet is that it affords the opportunity to effect long-term clinical remission through its disease-modifying properties. Furthermore, it has the potential to prevent the progression of allergic rhinitis to asthma, prevent new allergen sensitivities, and improve a patient's quality of life.
UR - http://www.scopus.com/inward/record.url?scp=85133777566&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85133777566&partnerID=8YFLogxK
U2 - 10.2500/aap.2022.43.220033
DO - 10.2500/aap.2022.43.220033
M3 - Article
C2 - 35818144
AN - SCOPUS:85133777566
SN - 1088-5412
VL - 43
SP - 260
EP - 266
JO - Allergy and Asthma Proceedings
JF - Allergy and Asthma Proceedings
IS - 4
ER -